Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARGOS THERAPEUTICS INCARGS · Entity 167312 | Director | January 19, 2017 | January 20, 2017 |
| Beyond Air, Inc.XAIR · Entity 8379 | Director | November 04, 2025 | November 07, 2025 |
| Disc Medicine, Inc.FSDC · Entity 2273 | Director | August 11, 2020 | August 12, 2020 |
| Horizon Therapeutics Public Ltd CoHZNP · Entity 109157 | EVP, Chief Business Officer | March 23, 2019 | March 25, 2019 |
| SANGAMO THERAPEUTICS, INCSGMO · Entity 7038 | Director | June 12, 2025 | June 16, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARGOS THERAPEUTICS INC
Report date January 19, 2017 · Filed January 20, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.85 · Expires 2027-01-18 | Direct | 9,500 |
Reported balance
After 2017-01-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-19 · Grant · Acquired 9,500 · Balance 9,500 |
Beyond Air, Inc.
Report date November 04, 2025 · Filed November 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80 | Direct | 0 |
Reported balance
After 2025-11-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-04 · Disposition to issuer · Disposed 4,500 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 | Direct | 4,500 |
Reported balance
After 2025-11-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-11-04 · Grant · Acquired 4,500 · Balance 4,500 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80 | Direct | 0 |
Reported balance
After 2025-11-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-11-04 · Disposition to issuer · Disposed 2,000 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 | Direct | 2,000 |
Reported balance
After 2025-11-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-11-04 · Grant · Acquired 2,000 · Balance 2,000 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80 | Direct | 0 |
Reported balance
After 2025-11-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-11-04 · Disposition to issuer · Disposed 1,500 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 | Direct | 1,500 |
Reported balance
After 2025-11-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-11-04 · Grant · Acquired 1,500 · Balance 1,500 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80 | Direct | 0 |
Reported balance
After 2025-11-04 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-11-04 · Disposition to issuer · Disposed 1,250 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 | Direct | 1,250 |
Reported balance
After 2025-11-04 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-11-04 · Grant · Acquired 1,250 · Balance 1,250 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80 | Direct | 0 |
Reported balance
After 2025-11-04 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-11-04 · Disposition to issuer · Disposed 1,250 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 | Direct | 1,250 |
Reported balance
After 2025-11-04 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-11-04 · Grant · Acquired 1,250 · Balance 1,250 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80 | Direct | 0 |
Reported balance
After 2025-11-04 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2025-11-04 · Disposition to issuer · Disposed 50 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 | Direct | 50 |
Reported balance
After 2025-11-04 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2025-11-04 · Grant · Acquired 50 · Balance 50 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80 | Direct | 0 |
Reported balance
After 2025-11-04 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2025-11-04 · Disposition to issuer · Disposed 1,250 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 | Direct | 1,250 |
Reported balance
After 2025-11-04 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2025-11-04 · Grant · Acquired 1,250 · Balance 1,250 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.89 | Direct | 0 |
Reported balance
After 2025-11-04 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2025-11-04 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 | Direct | 10,000 |
Reported balance
After 2025-11-04 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2025-11-04 · Grant · Acquired 10,000 · Balance 10,000 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged.
F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Disc Medicine, Inc.
Report date August 11, 2020 · Filed August 12, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-08-11 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
Horizon Therapeutics Public Ltd Co
Report date March 23, 2019 · Filed March 25, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 17,267 |
Ending reported balance
After 2019-03-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-03-23 · Exercise / conversion · Acquired 31,000 · Balance 31,000 F1: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Row 2 · 2019-03-23 · Tax withholding · Disposed 13,733 · Balance 17,267 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-03-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-03-23 · Exercise / conversion · Disposed 31,000 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F3: On March 23, 2015, the reporting person was granted 124,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Robert F. Carey III Trust dated 4/24/2001 | 249,091 |
Reported balance
Holding disclosure · report date 2019-03-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 249,091 F2: Includes 40,311 shares previously reported as directly held by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
F2: Includes 40,311 shares previously reported as directly held by the Reporting Person.
F3: On March 23, 2015, the reporting person was granted 124,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
SANGAMO THERAPEUTICS, INC
Report date June 12, 2025 · Filed June 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 99,600 |
Reported balance
After 2025-06-12 transaction · row 1
1 source rowRow 1 · 2025-06-12 · Grant · Acquired 25,000 · Balance 99,600 F1: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2035-06-11 | Direct | 50,000 |
Reported balance
After 2025-06-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-12 · Grant · Acquired 50,000 · Balance 50,000 F2: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.
F2: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 18, 2023 Filed Dec 19, 2023 17:13 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 1,200,000 | $1.64 | $1,962,000.00 |
DisclosureSEC source: 0001493152-23-045447 · ownership.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,374,454 F1 · balance_after: This figure reflects gifts made by the reporting person, as disclosed in a Form 5 filed on December 14, 2023, and the correction of a clerical error included in the reporting person's Form 4 filed on August 29, 2023 and Form 4 filed on August 22, 2023. Read SEC document |
| August 28, 2023 Filed Aug 29, 2023 16:10 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 250,000 | $2.70 | $673,750.00 |
DisclosureSEC source: 0001493152-23-030532 · ownership.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,225,160 Read SEC document |
| August 21, 2023 Filed Aug 22, 2023 16:10 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 75,050 | $2.76 | $207,453.21 |
DisclosureSEC source: 0001493152-23-029825 · ownership.xml · nonDerivative · entry 2 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 975,160 F2 · price: This price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.655 to $2.78, inclusive. The reporting person undertakes to provide to Beyond Air, Inc., any security holder of Beyond Air, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| August 18, 2023 Filed Aug 22, 2023 16:10 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 13,614 | $2.64 | $35,939.60 |
DisclosureSEC source: 0001493152-23-029825 · ownership.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 900,110 F1 · price: This price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.635 to $2.64, inclusive. The reporting person undertakes to provide to Beyond Air, Inc., any security holder of Beyond Air, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:47 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 27,750 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001209191-23-034389 · doc4.xml · derivative · entry 2 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,750 Underlying: Common Stock · 27,750 shares Expires 2033-05-31 F2 · derivative.exercise_date: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:47 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 13,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034389 · doc4.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,600 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit grant that will fully vest on the earlier of (a) June 1, 2024 or (b) the day prior to the 2024 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| March 30, 2023 Filed Mar 30, 2023 18:39 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 10,000 | $6.45 | $64,500.00 |
DisclosureSEC source: 0001493152-23-009860 · ownership.xml · nonDerivative · entry 2 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 886,496 Read SEC document |
| March 29, 2023 Filed Mar 30, 2023 18:39 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 10,000 | $6.30 | $63,000.00 |
DisclosureSEC source: 0001493152-23-009860 · ownership.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 876,496 Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 16:15 UTC | Beyond Air, Inc. XAIR · Entity 8379 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $6.28 | $0.00 |
DisclosureSEC source: 0001493152-23-010272 · ownership.xml · derivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-03-28 F1 · derivative.exercise_date: The option will vest as to 25% of the shares of common stock underlying the option on December 31, 2023, with the remainder vesting in equal annual installments on December 31 of each of the three ensuing years thereafter until vested in full. Read SEC document |
| March 16, 2023 Filed Dec 14, 2023 21:12 UTC | Beyond Air, Inc. XAIR · Entity 8379 | GiftCommon Stock | 28,656 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-044944 · ownership.xml · nonDerivative · entry 3 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 835,840 F1 · balance_after: This figure reflects the reporting person's shareholding as of the issuer's fiscal year end, on March 31, 2023. As of December 14, 2023, the reporting person held 1,174,454 shares of the issuer's common stock, which reflect the gifts disclosed in this Form 5 and the correction of a clerical error included in the reporting person's Form 4 filed on August 29, 2023 and Form 4 filed on August 22, 2023. Read SEC document |
| March 14, 2023 Filed Mar 15, 2023 16:05 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 10,000 | $6.85 | $68,500.00 |
DisclosureSEC source: 0001493152-23-007733 · ownership.xml · nonDerivative · entry 2 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 866,496 Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 16:05 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 4,173 | $6.15 | $25,663.95 |
DisclosureSEC source: 0001493152-23-007733 · ownership.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 856,496 Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 16:05 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 10,000 | $5.95 | $59,500.00 |
DisclosureSEC source: 0001493152-23-007121 · ownership.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 852,323 Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 16:15 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 20,000 | $5.75 | $115,000.00 |
DisclosureSEC source: 0001493152-22-035044 · ownership.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 842,323 Read SEC document |
| December 02, 2022 Filed Dec 14, 2023 21:12 UTC | Beyond Air, Inc. XAIR · Entity 8379 | GiftCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-044944 · ownership.xml · nonDerivative · entry 2 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 864,496 Read SEC document |
| November 29, 2022 Filed Nov 30, 2022 16:05 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 15,000 | $5.75 | $86,248.50 |
DisclosureSEC source: 0001493152-22-034023 · ownership.xml · nonDerivative · entry 2 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 822,323 F2 · balance_after: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.74 to $5.75, inclusive. The reporting person undertakes to provide to Beyond Air, Inc., any security holder of Beyond Air, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| November 28, 2022 Filed Nov 30, 2022 16:05 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 15,000 | $5.75 | $86,242.50 |
DisclosureSEC source: 0001493152-22-034023 · ownership.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 807,323 F1 · balance_after: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.74 to $5.75, inclusive. The reporting person undertakes to provide to Beyond Air, Inc., any security holder of Beyond Air, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| November 18, 2022 Filed Nov 18, 2022 20:35 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 20,000 | $5.80 | $116,000.00 |
DisclosureSEC source: 0001493152-22-032980 · ownership.xml · nonDerivative · entry 3 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 792,323 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.75 to $5.85, inclusive. The reporting person undertakes to provide to Beyond Air, Inc., any security holder of Beyond Air, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| November 17, 2022 Filed Nov 18, 2022 20:35 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 20,000 | $5.90 | $118,000.00 |
DisclosureSEC source: 0001493152-22-032980 · ownership.xml · nonDerivative · entry 2 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 772,323 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.80 to $6.00, inclusive. The reporting person undertakes to provide to Beyond Air, Inc., any security holder of Beyond Air, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 20:35 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 10,000 | $6.00 | $60,000.00 |
DisclosureSEC source: 0001493152-22-032980 · ownership.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 752,323 Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 16:45 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 175,000 | $6.45 | $1,128,295.00 |
DisclosureSEC source: 0001493152-22-018554 · ownership.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 742,323 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.25 to $6.50, inclusive. The reporting person undertakes to provide to Beyond Air, Inc., any security holder of Beyond Air, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| May 03, 2022 Filed Dec 14, 2023 21:12 UTC | Beyond Air, Inc. XAIR · Entity 8379 | GiftCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-044944 · ownership.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 880,496 Read SEC document |
| April 05, 2022 Filed Apr 6, 2022 16:15 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 20,000 | $6.71 | $134,200.00 |
DisclosureSEC source: 0001493152-22-009279 · ownership.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 567,323 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.69 to $6.72, inclusive. The reporting person undertakes to provide to Beyond Air, Inc., any security holder of Beyond Air, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| March 25, 2022 Filed Mar 28, 2022 09:34 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 22,500 | $6.65 | $149,625.00 |
DisclosureSEC source: 0001493152-22-007824 · ownership.xml · nonDerivative · entry 2 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 547,323 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.60 to $6.75, inclusive. The reporting person undertakes to provide to Beyond Air, Inc., any security holder of Beyond Air, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| March 24, 2022 Filed Mar 28, 2022 09:34 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 3,685 | $6.58 | $24,247.30 |
DisclosureSEC source: 0001493152-22-007824 · ownership.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 524,823 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.58 to $6.60, inclusive. The reporting person undertakes to provide to Beyond Air, Inc., any security holder of Beyond Air, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| March 17, 2022 Filed Mar 21, 2022 16:32 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 20,000 | $6.75 | $135,000.00 |
DisclosureSEC source: 0001493152-22-007364 · ownership.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 521,138 Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 08:33 UTC | Beyond Air, Inc. XAIR · Entity 8379 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $6.87 | $0.00 |
DisclosureSEC source: 0001493152-22-006147 · ownership.xml · derivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-03-02 F1 · derivative.exercise_date: The option will vest as to 25% of the shares of common stock underlying the option on December 31, 2022, with the remainder vesting in equal annual installments on December 31 of each of the three ensuing years thereafter until vested in full. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:07 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0001209191-22-014126 · doc4.xml · derivative · entry 2 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-02-24 F2 · derivative.exercise_date: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:07 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014126 · doc4.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,700 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit grant that will fully vest on the first anniversary of the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| December 22, 2021 Filed Dec 27, 2021 16:15 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 10,000 | $9.50 | $95,000.00 |
DisclosureSEC source: 0001493152-21-032513 · ownership.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 518,418 Read SEC document |
| November 23, 2021 Filed Nov 26, 2021 17:16 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 5,000 | $12.35 | $61,750.00 |
DisclosureSEC source: 0001493152-21-029935 · ownership.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 508,418 Read SEC document |
| November 22, 2021 Filed Nov 24, 2021 16:10 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 10,000 | $12.05 | $120,500.00 |
DisclosureSEC source: 0001493152-21-029832 · ownership.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 503,418 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.90 to $12.20, inclusive. The reporting person undertakes to provide to Beyond Air, Inc., any security holder of Beyond Air, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 16:50 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 12,000 | $14.10 | $169,200.00 |
DisclosureSEC source: 0001493152-21-029701 · ownership.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 493,418 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.90 to $14.50, inclusive. The reporting person undertakes to provide to Beyond Air, Inc., any security holder of Beyond Air, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 16:21 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 350,000 | $5.36 | $1,876,000.00 |
DisclosureSEC source: 0001493152-21-014866 · ownership.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 481,418 Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 07:42 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 17,000 | $5.70 | $96,900.00 |
DisclosureSEC source: 0001493152-21-005438 · ownership.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,418 Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 19:55 UTC | Beyond Air, Inc. XAIR · Entity 8379 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001493152-21-005622 · ownership.xml · derivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-03-03 F1 · derivative.exercise_date: The option will vest as to 25% of the shares of common stock underlying the option on December 31, 2021, with the remainder vesting in equal annual installments on December 31 of each of the three ensuing years thereafter until vested in full. Read SEC document |
| February 26, 2021 Filed Feb 18, 2022 08:00 UTC | Beyond Air, Inc. XAIR · Entity 8379 | GiftCommon Stock | 17,280 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-004914 · ownership.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 501,138 Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 01:56 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 16,400 | $0.00 Strike: $11.19 | $0.00 |
DisclosureSEC source: 0001209191-21-015497 · doc4.xml · derivative · entry 2 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,400 Underlying: Common Stock · 16,400 shares Expires 2031-02-24 F3 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended). The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Continuous Service (as defined in the 2018 EIP, as amended) over the 12-month period measured from the grant date and subject to acceleration as provided in the 2018 EIP, as amended. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 01:56 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 8,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015497 · doc4.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,200 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the first anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")), through such date and subject to acceleration as provided in the 2018 EIP, as amended. F2 · balance_after: Includes 10,000 shares of common stock issuable upon settlement of RSUs subject to Reporting Person's May 18, 2020 RSU grant that will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the Issuer's 2021 annual stockholders meeting, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended. Read SEC document |
| February 18, 2021 Filed Feb 18, 2021 16:11 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 15,000 | $6.67 | $100,050.00 |
DisclosureSEC source: 0001493152-21-004260 · ownership.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,418 Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 17:00 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 10,000 | $5.70 | $57,000.00 |
DisclosureSEC source: 0001493152-20-016769 · ownership.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,418 Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 17:00 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 50,000 | $5.65 | $282,500.00 |
DisclosureSEC source: 0001493152-20-016209 · ownership.xml · nonDerivative · entry 2 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,418 Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 17:00 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 10,000 | $5.50 | $55,000.00 |
DisclosureSEC source: 0001493152-20-016209 · ownership.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,418 Read SEC document |
| August 13, 2020 Filed Aug 17, 2020 18:51 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 5,000 | $5.30 | $26,500.00 |
DisclosureSEC source: 0001493152-20-016121 · ownership.xml · nonDerivative · entry 2 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,418 Read SEC document |
| August 13, 2020 Filed Aug 17, 2020 18:51 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 5,000 | $5.45 | $27,250.00 |
DisclosureSEC source: 0001493152-20-016121 · ownership.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,418 Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:13 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $10.46 | $0.00 |
DisclosureSEC source: 0001209191-20-030947 · doc4.xml · derivative · entry 2 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-05-17 F2 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:13 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-030947 · doc4.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| May 18, 2020 Filed Jun 3, 2020 20:27 UTC Amendment | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $10.46 | $0.00 |
DisclosureSEC source: 0001209191-20-034013 · doc4a.xml · derivative · entry 2 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-17 F3 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended). The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Continuous Service (as defined in the 2018 EIP, as amended) over the 12-month period measured from the grant date and subject to acceleration as provided in the 2018 EIP, as amended. Read SEC document |
| May 18, 2020 Filed Jun 3, 2020 20:27 UTC Amendment | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034013 · doc4a.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")), through such date and subject to acceleration as provided in the 2018 EIP, as amended. F2 · shares: This Form 4/A is being filed solely to correct the stated grant amounts which were erroneously reported on Form 4 filed on behalf of the Reporting Person on May 20, 2020. Pursuant to the 2018 EIP, as amended, and the Automatic Grant Program for Non-Employee Directors thereunder, the annual grant amounts increased effective with the approval of the 2018 EIP, as amended, by the stockholders of the Issuer on May 18, 2020. Such previously filed Form 4 incorrectly stated grant amounts pursuant to the Automatic Grant Program for Non-Employee Directors prior to such amendment and restatement of the 2018 Equity Incentive Plan. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 21:04 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $9.38 | $0.00 |
DisclosureSEC source: 0001209191-19-036434 · doc4.xml · derivative · entry 2 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-09 F2 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.